Preliminary Report - ID Mapping
Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision | |||
covid:unpublished [2021/01/08 17:06] biogridadmin |
covid:unpublished [2021/04/24 15:17] (current) biogridadmin |
||
---|---|---|---|
Line 131: | Line 131: | ||
| **888800000162** | **[[https://doi.org/10.1101/2020.12.03.409318|10.1101/2020.12.03.409318]]** | Bertoglio F (2020) | **[[https://thebiogrid.org/226415/publication|A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations]]** | | | **888800000162** | **[[https://doi.org/10.1101/2020.12.03.409318|10.1101/2020.12.03.409318]]** | Bertoglio F (2020) | **[[https://thebiogrid.org/226415/publication|A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations]]** | | ||
| **888800000163** | **[[https://doi.org/10.1101/2020.11.06.368191|10.1101/2020.11.06.368191]]** | Kraus A (2020) | **[[https://thebiogrid.org/226416/publication|A zebrafish model for COVID-19 recapitulates olfactory and cardiovascular pathophysiologies caused by SARS-CoV-2]]** | | | **888800000163** | **[[https://doi.org/10.1101/2020.11.06.368191|10.1101/2020.11.06.368191]]** | Kraus A (2020) | **[[https://thebiogrid.org/226416/publication|A zebrafish model for COVID-19 recapitulates olfactory and cardiovascular pathophysiologies caused by SARS-CoV-2]]** | | ||
+ | | **888800000164** | **[[https://doi.org/10.1101/2020.12.23.424149|10.1101/2020.12.23.424149]]** | Noske G (2020) | **[[https://thebiogrid.org/226619/publication|A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process]]** | | ||
+ | | **888800000165** | **[[https://doi.org/10.1101/2020.12.18.423427|10.1101/2020.12.18.423427]]** | Zhao Y (2020) | **[[https://thebiogrid.org/226620/publication|SARS-CoV-2 spike protein interacts with and activates TLR4]]** | | ||
+ | | **888800000166** | **[[https://doi.org/10.1101/2020.12.19.423537|10.1101/2020.12.19.423537]]** | Kitamura N (2020) | **[[https://thebiogrid.org/226621/publication|An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity]]** | | ||
+ | | **888800000167** | **[[https://doi.org/10.1101/2020.12.23.424171|10.1101/2020.12.23.424171]]** | Schmitz A (2020) | **[[https://thebiogrid.org/226622/publication|A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism]]** | | ||
+ | | **888800000168** | **[[https://doi.org/10.1101/2020.12.31.424961|10.1101/2020.12.31.424961]]** | Chen Z (2021) | **[[https://thebiogrid.org/226623/publication|Comprehensive analysis of the host-virus interactome of SARS-CoV-2]]** | | ||
+ | | **888800000169** | **[[https://doi.org/10.1101/2020.12.21.423721|10.1101/2020.12.21.423721]]** | Avolio E (2020) | **[[https://thebiogrid.org/226624/publication|The SARS-CoV-2 spike protein disrupts the cooperative function of human cardiac pericytes - endothelial cells through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease]]** | | ||
+ | | **888800000170** | **[[https://doi.org/10.1101/2020.12.19.423584|10.1101/2020.12.19.423584]]** | Garcia-Dorival I (2020) | **[[https://thebiogrid.org/226625/publication|Identification of NPC1 as a novel SARS-CoV-2 intracellular target]]** | | ||
+ | | **888800000171** | **[[https://doi.org/10.1101/2020.12.26.424423|10.1101/2020.12.26.424423]]** | Durdagi S (2020) | **[[https://thebiogrid.org/226626/publication|The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies]]** | | ||
+ | | **888800000172** | **[[https://doi.org/10.1101/2020.12.18.423415|10.1101/2020.12.18.423415]]** | Madan T (2020) | **[[https://thebiogrid.org/226627/publication|A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples]]** | | ||
+ | | **888800000173** | **[[https://doi.org/10.1101/2020.12.29.424698|10.1101/2020.12.29.424698]]** | Yang X (2020) | **[[https://thebiogrid.org/226628/publication|An Ultrasensitive Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and in vitro]]** | | ||
+ | | **888800000174** | **[[https://doi.org/10.1101/2020.12.20.422820|10.1101/2020.12.20.422820]]** | Fiedler S (2020) | **[[https://thebiogrid.org/226629/publication|In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum]]** | | ||
+ | | **888800000175** | **[[https://doi.org/10.1101/2020.12.22.422708|10.1101/2020.12.22.422708]]** | Shepley-McTaggart A (2020) | **[[https://thebiogrid.org/226630/publication|SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1]]** | | ||
+ | | **888800000176** | **[[https://doi.org/10.1101/2020.12.18.423418|10.1101/2020.12.18.423418]]** | Hsieh M-H (2020) | **[[https://thebiogrid.org/226631/publication|Human Surfactant Protein D Binds S1 and Receptor Binding Domain of Spike protein and acts as an entry inhibitor of SARS-CoV-2 Pseudotyped viral particles in vitro]]** | | ||
+ | | **888800000177** | **[[https://doi.org/10.1101/2020.12.16.422677|10.1101/2020.12.16.422677]]** | Kuzikov M (2020) | **[[https://thebiogrid.org/226632/publication|Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen]]** | | ||
+ | | **888800000178** | **[[https://doi.org/10.1101/2020.12.30.424801|10.1101/2020.12.30.424801]]** | Woo HG (2020) | **[[https://thebiogrid.org/226633/publication|Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro]]** | | ||
+ | | **888800000179** | **[[https://doi.org/10.1101/2020.12.26.424422|10.1101/2020.12.26.424422]]** | Xu W (2020) | **[[https://thebiogrid.org/226634/publication|Extensive High-Order Complexes within SARS-CoV-2 Proteome Revealed by Compartmentalization-Aided Interaction Screening]]** | | ||
+ | | **888800000180** | **[[https://doi.org/10.1101/2020.12.09.417741|10.1101/2020.12.09.417741]]** | Armstrong L (2020) | **[[https://thebiogrid.org/226635/publication|Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies]]** | | ||
+ | | **888800000181** | **[[https://doi.org/10.1101/2020.12.29.424682|10.1101/2020.12.29.424682]]** | Kuznetsov A (2020) | **[[https://thebiogrid.org/226636/publication|ACE2 peptide fragment interacts with several sites on the SARS-CoV-2 spike protein S1]]** | | ||
+ | | **888800000182** | **[[https://doi.org/10.1101/2021.01.21.427657|10.1101/2021.01.21.427657]]** | Choi R (2021) | **[[https://thebiogrid.org/226858/publication|High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.]]** | | ||
+ | | **888800000183** | **[[https://doi.org/10.1101/2021.01.12.426388|10.1101/2021.01.12.426388]]** | Kneller DW (2021) | **[[https://thebiogrid.org/226859/publication|Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease]]** | | ||
+ | | **888800000184** | **[[https://doi.org/10.1101/2021.01.17.427000|10.1101/2021.01.17.427000]]** | Wan Y (2021) | **[[https://thebiogrid.org/226860/publication|Comprehensive mapping of SARS-CoV-2 interactions in vivo reveals functional virus-host interactions]]** | | ||
+ | | **888800000185** | **[[https://doi.org/10.1101/2021.01.19.427194|10.1101/2021.01.19.427194]]** | Tian R (2021) | **[[https://thebiogrid.org/226861/publication|BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2]]** | | ||
+ | | **888800000186** | **[[https://doi.org/10.1101/2021.01.11.426269|10.1101/2021.01.11.426269]]** | Zhu X (2021) | **[[https://thebiogrid.org/226862/publication|Cryo-EM Structure of the N501Y SARS-CoV-2 Spike Protein in Complex with a Potent Neutralizing Antibody]]** | | ||
+ | | **888800000187** | **[[https://doi.org/10.1101/2021.01.05.425478|10.1101/2021.01.05.425478]]** | Kamle S (2021) | **[[https://thebiogrid.org/226863/publication|Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19]]** | | ||
+ | | **888800000188** | **[[https://doi.org/10.1101/2021.01.14.426695|10.1101/2021.01.14.426695]]** | Carnell GW (2021) | **[[https://thebiogrid.org/226864/publication|SARS-CoV-2 spike protein arrested in the closed state induces potent neutralizing responses]]** | | ||
+ | | **888800000189** | **[[https://doi.org/10.1101/2021.01.13.21249429|10.1101/2021.01.13.21249429]]** | Hultstrom M (2021) | **[[https://thebiogrid.org/226865/publication|Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients]]** | | ||
+ | | **888800000190** | **[[https://doi.org/10.1101/2021.01.19.427324|10.1101/2021.01.19.427324]]** | Suryadevara N (2021) | **[[https://thebiogrid.org/226866/publication|Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein]]** | | ||
+ | | **888800000191** | **[[https://doi.org/10.1101/2021.01.11.426218|10.1101/2021.01.11.426218]]** | Rapp M (2021) | **[[https://thebiogrid.org/226867/publication|Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class]]** | | ||
+ | | **888800000192** | **[[https://doi.org/10.1101/2021.01.07.425745|10.1101/2021.01.07.425745]]** | Saramago M (2021) | **[[https://thebiogrid.org/226868/publication|New targets for drug design: Importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2]]** | | ||
+ | | **888800000193** | **[[https://doi.org/10.1101/2021.01.12.426042|10.1101/2021.01.12.426042]]** | Siniavin AE (2021) | **[[https://thebiogrid.org/226869/publication|Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor]]** | | ||
+ | | **888800000194** | **[[https://doi.org/10.1101/2021.01.07.425806|10.1101/2021.01.07.425806]]** | Bell BN (2021) | **[[https://thebiogrid.org/226870/publication|Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library]]** | | ||
+ | | **888800000195** | **[[https://doi.org/10.1101/2021.01.20.427368|10.1101/2021.01.20.427368]]** | Carlos AJ (2021) | **[[https://thebiogrid.org/226871/publication|GRP78 binds SARS-CoV-2 Spike protein and ACE2 and GRP78 depleting antibody blocks viral entry and infection in vitro]]** | | ||
+ | | **888800000196** | **[[https://doi.org/10.1101/2021.01.05.425516|10.1101/2021.01.05.425516]]** | Verma R (2021) | **[[https://thebiogrid.org/226872/publication|RNA-protein interaction analysis of SARS-CoV-2 5'- and 3'-untranslated regions identifies an antiviral role of lysosome-associated membrane protein-2]]** | | ||
+ | | **888800000197** | **[[https://doi.org/10.1101/2021.01.29.428890|10.1101/2021.01.29.428890]]** | Berndt AJ (2021) | **[[https://thebiogrid.org/227046/publication|Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii]]** | | ||
+ | | **888800000198** | **[[https://doi.org/10.1101/2021.01.29.428834|10.1101/2021.01.29.428834]]** | Bayarri-Olmos R (2021) | **[[https://thebiogrid.org/227047/publication|The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization]]** | | ||
+ | | **888800000199** | **[[https://doi.org/10.1101/2021.02.03.429601|10.1101/2021.02.03.429601]]** | Prahlad J (2021) | **[[https://thebiogrid.org/227048/publication|Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain]]** | | ||
+ | | **888800000200** | **[[https://doi.org/10.1101/2021.02.03.429625|10.1101/2021.02.03.429625]]** | Khalili Yazdi A (2021) | **[[https://thebiogrid.org/227049/publication|A high-throughput radioactivity-based assay for screening SARS-CoV-2 nsp10-nsp16 complex]]** | | ||
+ | | **888800000201** | **[[https://doi.org/10.1101/2021.02.01.429176|10.1101/2021.02.01.429176]]** | Caillet-Saguy C (2021) | **[[https://thebiogrid.org/227050/publication|Host PDZ-containing proteins targeted by SARS-Cov-2]]** | | ||
+ | | **888800000202** | **[[https://doi.org/10.1101/2021.02.11.430866|10.1101/2021.02.11.430866]]** | Liu H (2021) | **[[https://thebiogrid.org/227051/publication|A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection]]** | | ||
+ | | **888800000203** | **[[https://doi.org/10.1101/2021.02.02.429311|10.1101/2021.02.02.429311]]** | Ma H (2021) | **[[https://thebiogrid.org/227052/publication|Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain]]** | | ||
+ | | **888800000204** | **[[https://doi.org/10.1101/2021.02.19.424337|10.1101/2021.02.19.424337]]** | Devkota K (2021) | **[[https://thebiogrid.org/227053/publication|Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors]]** | | ||
+ | | **888800000205** | **[[https://doi.org/10.1101/2021.02.13.431008|10.1101/2021.02.13.431008]]** | Shen Z (2021) | **[[https://thebiogrid.org/227054/publication|Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures]]** | | ||
+ | | **888800000206** | **[[https://doi.org/10.1101/2021.02.17.431617|10.1101/2021.02.17.431617]]** | Bollavaram K (2021) | **[[https://thebiogrid.org/227055/publication|Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to Proteolysis by Cathepsins B, K, L, S, and V]]** | | ||
+ | | **888800000207** | **[[https://doi.org/10.1101/2021.01.31.429023|10.1101/2021.01.31.429023]]** | Minasov G (2021) | **[[https://thebiogrid.org/227056/publication|Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16]]** | | ||
+ | | **888800000208** | **[[https://doi.org/10.1101/2021.02.03.429355|10.1101/2021.02.03.429355]]** | Graham C (2021) | **[[https://thebiogrid.org/227057/publication|Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike]]** | | ||
+ | | **888800000209** | **[[https://doi.org/10.1101/2021.02.09.430451|10.1101/2021.02.09.430451]]** | Spelios MG (2021) | **[[https://thebiogrid.org/227058/publication|A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding]]** | | ||
+ | | **888800000210** | **[[https://doi.org/10.1101/2021.02.02.428884|10.1101/2021.02.02.428884]]** | Zhang G (2021) | **[[https://thebiogrid.org/227059/publication|The basis of a more contagious 501Y.V1 variant of SARS-COV-2]]** | | ||
+ | | **888800000211** | **[[https://doi.org/10.1101/2021.02.16.431021|10.1101/2021.02.16.431021]]** | Arutyunova E (2021) | **[[https://thebiogrid.org/227060/publication|N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 Mpro]]** | | ||
+ | | **888800000212** | **[[https://doi.org/10.1101/2021.02.07.429299|10.1101/2021.02.07.429299]]** | Gu C (2021) | **[[https://thebiogrid.org/227061/publication|A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques]]** | | ||
+ | | **888800000213** | **[[https://doi.org/10.1101/2021.02.04.429751|10.1101/2021.02.04.429751]]** | Slavin M (2021) | **[[https://thebiogrid.org/227062/publication|Targeted in situ cross-linking mass spectrometry and integrative modeling reveal the architectures of Nsp1, Nsp2, and Nucleocapsid proteins from SARS-CoV-2]]** | | ||
+ | | **888800000214** | **[[https://doi.org/10.1101/2021.02.08.430344|10.1101/2021.02.08.430344]]** | Zhao H (2021) | **[[https://thebiogrid.org/227063/publication|Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids]]** | | ||
+ | | **888800000215** | **[[https://doi.org/10.1101/2021.02.14.431117|10.1101/2021.02.14.431117]]** | Tian F (2021) | **[[https://thebiogrid.org/227064/publication|Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2]]** | | ||
+ | | **888800000216** | **[[https://doi.org/10.1101/2021.02.17.431755|10.1101/2021.02.17.431755]]** | Zhao Y (2021) | **[[https://thebiogrid.org/227065/publication|SARS-CoV-2 nucleocapsid protein dually regulates innate immune responses]]** | |